| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 09/27/2023 | 412.25% | Needham | → $23 | Reiterates | Buy → Buy |
| 09/08/2023 | 234.08% | Wedbush | → $15 | Maintains | Outperform |
| 08/09/2023 | 412.25% | Needham | → $23 | Reiterates | Buy → Buy |
| 08/08/2023 | 256.35% | HC Wainwright & Co. | → $16 | Reiterates | Buy → Buy |
| 08/04/2023 | 256.35% | HC Wainwright & Co. | $19 → $16 | Maintains | Buy |
| 07/27/2023 | 412.25% | Needham | → $23 | Reiterates | Buy → Buy |
| 05/10/2023 | 412.25% | Needham | → $23 | Reiterates | → Buy |
| 04/19/2023 | 412.25% | Needham | → $23 | Reiterates | → Buy |
| 03/23/2023 | 33.63% | Jefferies | $4.5 → $6 | Upgrades | Hold → Buy |
| 03/23/2023 | 412.25% | Needham | → $23 | Reiterates | → Buy |
| 02/17/2023 | 345.43% | HC Wainwright & Co. | → $20 | Reiterates | → Buy |
| 02/17/2023 | 412.25% | Needham | → $23 | Reiterates | → Buy |
| 05/26/2022 | 11.36% | Jefferies | → $5 | Initiates Coverage On | → Hold |
| 05/11/2022 | 345.43% | HC Wainwright & Co. | $33 → $20 | Maintains | Buy |
| 03/16/2022 | 456.79% | Wedbush | $35 → $25 | Maintains | Outperform |
| 02/07/2022 | 634.97% | HC Wainwright & Co. | → $33 | Initiates Coverage On | → Buy |
| 11/29/2021 | 412.25% | Needham | → $23 | Initiates Coverage On | → Buy |
| 08/18/2020 | 679.51% | Wedbush | → $35 | Initiates Coverage On | → Outperform |
| 08/18/2020 | 634.97% | B of A Securities | → $33 | Initiates Coverage On | → Buy |
| 08/18/2020 | — | Cowen & Co. | Initiates Coverage On | → Outperform | |
| 08/18/2020 | 790.87% | Piper Sandler | → $40 | Initiates Coverage On | → Overweight |
What is the target price for Inozyme Pharma (INZY)?
The latest price target for Inozyme Pharma (NASDAQ: INZY) was reported by Needham on September 27, 2023. The analyst firm set a price target for $23.00 expecting INZY to rise to within 12 months (a possible 412.25% upside). 12 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Inozyme Pharma (INZY)?
The latest analyst rating for Inozyme Pharma (NASDAQ: INZY) was provided by Needham, and Inozyme Pharma reiterated their buy rating.
When is the next analyst rating going to be posted or updated for Inozyme Pharma (INZY)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Inozyme Pharma, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Inozyme Pharma was filed on September 27, 2023 so you should expect the next rating to be made available sometime around September 27, 2024.
Is the Analyst Rating Inozyme Pharma (INZY) correct?
While ratings are subjective and will change, the latest Inozyme Pharma (INZY) rating was a reiterated with a price target of $0.00 to $23.00. The current price Inozyme Pharma (INZY) is trading at is $4.49, which is within the analyst's predicted range.